Recommendations - GRADE working group

gradeworkinggroup.org

Recommendations - GRADE working group

Evidence Profiles

Oseltamivir - H5N1

Qualität aller

Endpunkte

No of studies

(Ref)

Healthy adults:

Design Limitations Consistency Directness

Other

considerations

Oseltamivir

Placebo

Relative

(95% CI)

Absolute

(95% CI)

Mortality

0 - - - - - - - - - 9

Hospitalisation (Hospitalisations from influenza – influenza cases only)

5

(TJ 06)

Randomised

trial

Duration of hospitalization

No limitations One trial only

Major Imprecise or

uncertainty sparse data (-1)

(-2) 1

- - OR 0.22

(0.02 to 2.16)

- ⊕

Very low

0 - - - - - - - - - - 7

LRTI (Pneumonia - influenza cases only)

5

(TJ 06)

5 3

(TJ 06)

(DT 03)

2 6

(TJ 06)

Outbreak control

Randomised

trial

Randomised

trials

Randomised

trials

No limitations One trial only Major Imprecise or

2/982

- uncertainty sparse data (-1) 2 (0.2%)

(-2) 1

9/662

(1.4%)

RR 0.149

(0.03 to 0.69)

No limitations 4 Important Major - - - HR 1.30 3

(-1) 5 (-2) 1

inconsistency uncertainty

(1.13 to 1.50)

None - - - WMD -0.73 8

No limitations

-7

Major

(-2) 1

uncertainty

(-0.99 to -0.47)

- ⊕

Very low

- ⊕

Very low

0 - - - - - - - - - - 4

Resistance

0 - - - - - - - - - - 7

Serious adverse effects (Mention of significant or serious adverse effects)

0 9 - - - - - - - - - - 7

Minor adverse effects 10 (number and seriousness of adverse effects)

3 11

(TJ 06)

Cost of drugs

Randomised

trials

Quality assessment

Viral shedding (Mean nasal titre of excreted virus at 24h)

-

No of patients

Duration of disease (Time to alleviation of symptoms/median time to resolution of symptoms – influenza cases only)

Imprecise or

- - OR range 15

No limitations

-12

Some

(-1) 13

uncertainty sparse data (-1) 14 (0.56 to 1.80)

Summary of findings

⊕⊕

Low

- ⊕⊕

Low

0 - - - - - - - - - - 4

Effect

Quality

Importance

6

8

5

4

Weitere Magazine dieses Users
Ähnliche Magazine